Cianferotti, L.
Porcu, G.
Ronco, R.
Adami, G.
Alvaro, R.
Bogini, R.
Caputi, A. P.
Frediani, B.
Gatti, D.
Gonnelli, S.
Iolascon, G.
Lenzi, A.
Leone, S.
Michieli, R.
Migliaccio, S.
Nicoletti, T.
Paoletta, M.
Pennini, A.
Piccirilli, E.
Rossini, M.
Tarantino, U.
Brandi, M. L.
Corrao, G.
Biffi, A.
Funding for this research was provided by:
Università degli Studi di Milano - Bicocca
Article History
Received: 26 January 2023
Accepted: 21 July 2023
First Online: 21 August 2023
Declarations
:
: GA declares personal fees from Theramex, Amgen, BMS, Lilly, Fresenius Kabi and Galapagos. LC declares personal fees from UCB Pharma, Abiogen Pharma, Bruno Farmaceutici, Sandoz, Metagenics. DG has received honoraria as consultant for Eli-Lilly, Organon, MSD Italia. SG has received honoraria as consultant for UCB Pharma. SM has received honoraria as consultant for UCB, Eli-Lilly, Amgen. MLB has received (i) honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB; (ii) grants and/or speaker: Abiogen, Alexion, Amgen, Bruno Farmaceutici, Echolight, Eli Lilly, Kyowa Kirin, SPA, Theramex, UCB Pharma; (iii) consultant: Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB Pharma. GC received research support from the European Community (EC), the Italian Agency of Drug (AIFA), and the Italian Ministry for University and Research (MIUR). He took part to a variety of projects that were funded by pharmaceutical companies (i.e., Novartis, GSK, Roche, AMGEN, and BMS). He also received honoraria as member of Advisory Board from Roche. No other potential conflicts of interest relevant to this article were disclosed. MR declares personal fees from Amgen, ABBvie, BMS, Eli Lilly, Galapagos, Menarini, Novartis, Pfizer, Sandoz, Theramex and UCB outside the submitted work. RM took part to a project funded by Abiogen Pharma. GI received honoraria as speaker by Eli-Lilly, Menarini, UCB Pharma. The other authors declare that they have no conflict of interest.